Report Tools

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

Published: January 2013 · Publisher: MarketLine
Alexion Pharmaceuticals, Inc. (Alexion) is engaged in biologic therapeutic products aimed at treating patients with ultra-rare disease states. In 2007, it gained marketing approval from the FDA for Soliris, which has since become the world’s ...
Report Type Case Studies
Language English
Format Electronic (PDF)
Pages24
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-2786
Price € 369,00
Options
  • Description
  • Table of Contents
  • Ask a Question
Introduction

Alexion Pharmaceuticals, Inc. (Alexion) is engaged in biologic therapeutic products aimed at treating patients with ultra-rare disease states. In 2007, it gained marketing approval from the FDA for Soliris, which has since become the world’s single most expensive drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Features and benefits

* The publisher's Case Studies describe topics such as innovative products, business models, and significant company acquisitions.
* Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends.

Highlights

Soliris is currently approved to treat two ultra-rare orphan diseases and is, according to Forbes, the most expensive drug in the world. Since its launch in 2007, Alexion has seen its revenues and stock price soar, reflecting its success and dramatic rise to prominence within the pharmaceuticals market.
Although the company enjoys exclusivity with Soliris for the time-being, this will become irrelevant by 2021, when its patent is due to expire, and generic versions of the drug will enjoy entry into the market.
In order to sustain growth going forward, Alexion is in the process of employing a number of strategies involving further R&D activities and acquisitions of other pharmaceutical and biotechnology companies, such as Taligen Therapeutics, Inc. and Enobia Pharma Corp.

Your key questions answered

* Through which strategies has Alexion achieved success with its sole product, Soliris, thus far?
* What has been the impact of Alexion's success with Soliris on its overall business?
* What future challenges does Alexion face, and how are they aiming to combat these challenges?
* What acquisitions have been made by Alexion in recent years, and what impact have they had on the company's overall business?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
O VERVIEW
Catalyst
Summary
ALEXION’S REVENUES HAVE SOARED RECENTLY
Pharmaceuticals is a broad, growing market
The pharmaceuticals market has experienced strong, steady growth
The pharmaceuticals market is fragmented
Niche positions in the market are enabled by patent protection and exclusivity rights
Alexion’s sole revenue driver is an orphan drug
The company’s cornerstone drug, Soliris, has an extremely rare application
Alexion’s revenues have soared following a high price and exclusivity
Success with Soliris has boosted the company’s market capitalization
ALEXION WILL FACE FUTURE CHALLENGES
Alexion has an overreliance on Soliris
Big Pharma companies have diversified operations
The reliance on Soliris is a major threat for Alexion
The “patent cliff” serves as a threat to Alexion
The impact of the “patent cliff” is an industry-wide issue
The “patent cliff” will directly impact Alexion
Big Pharma companies are entering the orphan market
Big Pharma companies are setting up stand-alone units to commercialize orphan drugs
Competition will come at the research and development stage
HOW ALEXION IS COMBATTING CHALLENGES
Alexion’s R&D activity is on the rise
Alexion’s R&D spending has increased with revenues
Alexion has established another niche application for Soliris
Further niche applications for Soliris are in the pipeline
The acquisition of Taligen has further developed Alexions’s pipeline
The acquisition of Taligen enhances Alexion’s R&D capability
The acquisition of Taligen may have removed a potential competitor
Further acquisitions have also added to Alexion’s pipeline
The deal with Orphatec has potential for further orphan activities
Alexion acquired Enobia for a relatively small fee
Enobia’s lead product candidate has a niche application
CONCLUSIONS
Alexion’s focus on niche demographics and orphan drugs continues to be a key revenue and profit driver
APPENDIX
Definitions
Sources
Further Reading
Ask the analyst
About the publisher
Disclaimer
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.